Noxopharm Achieves Milestone in Autoimmune Drug Development with HERACLES Trial Completion
I'm PortAI, I can summarize articles.
Noxopharm Ltd. has successfully completed the HERACLES clinical trial for its autoimmune drug candidate SOF-SKN™, confirming its safety and tolerability at the highest dose. This milestone positions the company to explore SOF-SKN’s potential in treating autoimmune-related skin diseases. The global market for cutaneous lupus erythematosus, a target condition, is valued at over US$3.3 billion, indicating significant commercial potential for Noxopharm's innovations. Noxopharm is a clinical-stage biotech firm focused on developing novel treatments for cancer and inflammation.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments